Tert-butyl 2-[7-amino-6-bromo-3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]thiomorpholine-4-carboxylate | 1057259-72-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Tert-butyl 2-[7-amino-6-bromo-3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]thiomorpholine-4-carboxylate
• CAS: 1057259-72-9
• 化学式: C₁₉H₂₄BrN₇O₂S
• 分子量: 494.415
• InChiKey: YNQMKSKEXGSPSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Tert-butyl 2-[7-amino-6-bromo-3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]thiomorpholine-4-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(thiomorpholin-2-yl)pyrazolo[1,5-a]pyrimidin-7-amine
  参考文献：
  名称：

  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2

  摘要：

  Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo [1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.114
• 作为产物：
  描述：

  Tert-butyl 2-[7-amino-3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]thiomorpholine-4-carboxylate 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 生成 Tert-butyl 2-[7-amino-6-bromo-3-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]thiomorpholine-4-carboxylate
  参考文献：
  名称：

  Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2

  摘要：

  Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo [1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.114

文献信息

• Pyrazolopyrimidines as cyclin dependent kinase inhibitors
  申请人：Guzi J. Timothy

  公开号：US20070225270A1

  公开（公告）日：2007-09-27

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一种新型的嘧唑并[1,5-a]嘧啶化合物类作为细胞周期蛋白依赖性激酶的抑制剂，制备这种化合物的方法，含有一种或多种这种化合物的制药组合物，制备包含一种或多种这种化合物的制药制剂的方法，以及使用这种化合物或制药组合物治疗、预防、抑制或缓解与CDKs相关的一种或多种疾病的方法。
• NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP1931677B1

  公开（公告）日：2016-04-20
• US7196078B2
  申请人：——

  公开号：US7196078B2

  公开（公告）日：2007-03-27
• US8580782B2
  申请人：——

  公开号：US8580782B2

  公开（公告）日：2013-11-12
• [EN] NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS<br/>[FR] NOUVEAUX PYRAZOLOPYRIMIDINES EN TANT QU'INHIBITEURS DES KINASES DEPENDANTES DES CYCLINES
  申请人：SCHERING CORP

  公开号：WO2007044449A2

  公开（公告）日：2007-04-19

  [EN] In its many embodiments, the present invention provides a novel class of pyrazolo[1 ,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
  [FR] Dans ses différents modes de réalisation, la présente invention a trait à une nouvelle classe de composés pyrazolo[1,5-a]pyrimidine en tant qu'inhibiteurs des kinases dépendantes des cyclines, à des procédés de préparation de tels composés, à des compositions pharmaceutiques contenant un ou plusieurs de ces composés, à la préparation de formulations pharmaceutiques comprenant un ou plusieurs de ces composés, et à des procédés de traitement, de prévention, d'inhibition, ou d'amélioration d'une ou de plusieurs maladies associées aux kinases dépendantes des cyclines mettant en oeuvre ces composés ou compositions pharmaceutiques.